Rybrevant Faspro is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma that is associated with human papillomavirus (HPV).
Food and Drug Administration · Official source · Updated
A Kansas business owner was sentenced to 12 months and one day in prison for failing to forward payroll taxes paid by his employees to the Internal Revenue Service (IRS).
Tax preparer sentenced to prison A Kansas tax preparer was sentenced to 36 months in prison for filing false income tax returns for his clients leading to a tax loss of more than $1.5 million.
Sanctions Against North Korea A Bosnian national was sentenced to 60 months in federal prison after pleading guilty to federal export and sanctions violations by conspiring and attempting to broker the sale of Man.
President Donald J. Trump unveiled the Trump Dividend — a historic $5,000 cash payment to every adult American citizen.
If the Republicans win the House of Representatives and the United States Senate, President Trump promises to issue a dividend to every adult citizen in the United States of America for $5,000.
The U.S. Food and Drug Administration granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the treatment of adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
The FDA also authorized the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with camizestrant.
The accelerated approval was granted to AstraZeneca.